Source: Merck Animal Health
Merck Animal Health announced that the U.S. Food and Drug Administration has granted conditional approval for EXZOLT™ CATTLE-CA1, a first-in-class topical parasiticide for cattle. The product, containing fluralaner, is the only conditionally approved treatment for both the prevention and treatment of New World screwworm (Cochliomyia hominivorax) larvae and for the treatment and control of cattle fever tick. New World screwworm poses a significant threat to U.S. agriculture, with the potential for severe economic losses to cattle producers.
EXZOLT CATTLE-CA1 is the first novel ectoparasiticide introduced for beef cattle in decades and addresses growing resistance concerns. Its approval was based on demonstrated safety and a reasonable expectation of effectiveness from global studies. The pour-on solution acts systemically and is approved for use in beef cattle two months and older and certain replacement dairy heifers, with specific use restrictions and a 98-day meat withdrawal period. The product will be available by prescription in early 2026, supporting efforts to protect cattle health and the U.S. beef supply.